Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A family of structurally related macrocyclic lactones, bryostatins, have recently been shown to display several intriguing pharmacologic properties. Bryostatins are biosynthetic products of bryozoa phyllum of marine animals. To extend the analyses of the biological activities of these highly unusual biosynthetic animal products, we have examined the effect of bryostatin 1 (bryo-1) on the steady-state expression of the human immunodeficiency virus receptor, CD4, by normal peripheral blood T lymphocytes. Incubation of the cells with 5 nM bryo-1 caused a substantial loss of CD4 from the cell surface, as analyzed by flow cytometry using anti-CD4 monoclonal antibody. The modulation of CD4 expression by bryo-1 was not due to a cytotoxicity effect: in the culture conditions where it modulated CD4, bryo-1 also stimulated the expression of the
interleukin 2
gene, as indicated by northern blot hybridization. In addition, incubation of the lymphocytes with nanomolar amounts of
protein kinase C
antagonist, staurosporine, resulted in the inhibition of the bryo-1-induced modulation of CD4 expression. The results of radioimmunoprecipitation analysis of detergent lysates of [35S] methionine-labeled lymphocytes strongly suggest that bryo-1 inhibits the glycosylation and expression of CD4 in a manner similar to that of tunicamycin.
...
PMID:Distinct modulatory effects of bryostatin 1 and staurosporine on the biosynthesis and expression of the HIV receptor protein (CD4) by T cells. 186 3
T lymphocytes and monocytes were exposed to microgravity and activated to produce
interleukin 2
and interleukin 1, respectively. When Jurkat T cells were triggered with monoclonal antibodies directed against the CD3/T cell receptor complex in the presence of THP-1 monocytes used as accessory cells, cell-to-cell contacts took place in microgravity leading to normal production of
interleukin 2
and interleukin 1, as compared to ground controls. In contrast, when cells were individually stimulated by soluble substances including a
protein kinase C
activating phorbol ester, the production of interleukin 1 and
interleukin 2
was dramatically inhibited during microgravity exposure. This result indicates that microgravity may affect the cellular target of phorbol ester.
...
PMID:Inhibition of phorbol ester-induced cell activation in microgravity. 191 66
The rate of the degradation of
interleukin 2
(
IL-2
) mRNA produced in stimulated human tonsillar lymphocytes was found to be significantly decreased in cells continuously stimulated with a calcium ionophore, A23187, and a phorbol ester, phorbol 12, 13-dibutylate (PDB) as compared with that in unstimulated cells. When the lymphocytes were stimulated with A23187 and PDB,
IL-2
mRNA reached a maximum level at 8 h and gradually decreased to almost the base line by 27 h.
IL-2
mRNA produced was rapidly degraded when the stimulants were washed out at 12 h and the cells further cultured in the presence of actinomycin D, which stops mRNA synthesis. However, the stability of
IL-2
mRNA was increased by the addition of PDB or A23187. A maximal effect was observed when both were added. The effect of PDB was dose-dependent and inhibited by the inhibitors of
protein kinase C
(
PKC
), staurosporine, and K252a, suggesting the involvement of
PKC
in the control of
IL-2
mRNA stability. The involvement of protein phosphorylation in the regulating mechanism of
IL-2
mRNA stability was supported by the fact that the addition of okadaic acid, which inhibits serine/threonine protein phosphatases, resulted in an increase in the stability of
IL-2
mRNA. Further study demonstrated that the rate of degradation of 32P-labeled
IL-2
mRNA, which was prepared by cell-free transcription of
IL-2
cDNA, in the polysomal fraction obtained from PDB-stimulated lymphocytes was decreased compared with that obtained from unstimulated lymphocytes. These results indicate the presence of a mechanism controlling the stability of
IL-2
mRNA that is regulated by
PKC
.
...
PMID:Stability of IL-2 mRNA in T lymphocytes is controlled by a protein kinase C-regulated mechanism. 196 89
Bryostatins are a novel class of
protein kinase C
activators which were isolated from the marine bryozoan Bugula neritina and found to possess both antineoplastic and immunoenhancing properties. In this report, we examined the relationship between the in vivo and in vitro antineoplastic effects of bryostatin 1. The in vivo antitumor activity of bryostatin 1 was demonstrated in a B16 melanoma pulmonary metastases model, in which treatment of tumor-bearing C57BL/6 mice with 5 days of bryostatin 1 resulted in a significant reduction in of the number of lung nodules (control, 87; bryostatin, 7). There was a clear dose-response effect, with the optimal antimelanoma dose being 100 micrograms/kg/day, but even low doses of bryostatin 1 of 1 micrograms/kg/day resulted in a 53% reduction in the number of metastases. Although bryostatin 1 shares many biological properties with the phorbol esters, parallel treatment with 12-O-tetradecanoyl 13-phorbol acetate was ineffective against B16 melanoma in vivo. Using a clonogenic assay, bryostatin 1 was found to have a direct antiproliferative effect against B16 melanoma. This inhibition occurred at relatively high bryostatin 1 concentrations (10(-6) M), in comparison with a sensitive cell line REH (10(-10) M). Treatment of mice with bryostatin 1 or preincubation of normal spleen cells with bryostatin 1 failed to enhance nonspecific cell-mediated cytotoxicity against B16 melanoma in vitro. Moreover, bryostatin 1 was found to inhibit both natural killer cell activity and
interleukin 2
generation of lymphokine-activated killer cells. Thus, a role for an in vivo immune enhancement mechanism as the basis for the antimelanoma activity observed with bryostatin 1 cannot be invoked from these experiments. These findings indicate that bryostatin 1 may act directly on the B16 melanoma pulmonary metastases. The precise mechanism whereby bryostatin exerts its antimelanoma effects remains unclear.
...
PMID:Successful treatment of murine melanoma with bryostatin 1. 198 85
Lymphocytes can be stimulated to proliferate in vitro by mitogens such as concanavalin A. The tumor-promoting phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) can enhance this proliferation, partly because of an increase in
interleukin 2
(
IL-2
) production. However, if lymphocytes are treated with TPA for 24 h before concanavalin A exposure,
IL-2
production and proliferation are depressed. The target of the action of TPA is
protein kinase C
, which is activated after a short exposure but down-regulated after a longer one. This study was designed to determine if the modulation of
IL-2
was separable from the modulation of
protein kinase C
. When phorbol esters phorbol 12-retinoate-13-acetate, phorbol 12,13-dibutyrate, 12-deoxyphorbol 13-phenylacetate, and 12-deoxyphorbol 13-phenylacetate-20-acetate, as well as nonphorbol tumor promoters mezerein, telocidin, and okadaic acid, were tested, all but okadaic acid reproduced the effects of TPA. However, 12-deoxyphorbol 13-phenylacetate and 12-deoxyphorbol 13-phenylacetate-20-acetate were required at nearly 100-fold higher concentrations than TPA to suppress
IL-2
production, suppress mitogenesis, and cause down-regulation of
protein kinase C
. A comparison of structures indicated that an R group at the 12-position was less important for
IL-2
production and mitogenesis than for down-regulation of
protein kinase C
and the suppression of mitogenesis. In no case was the modulation of
protein kinase C
separated from the effects on
IL-2
production and proliferation.
...
PMID:Differential activation and inhibition of lymphocyte proliferation by phorbol esters, mezerein, teleocidin, and okadaic acid. 198 10
Phorbol esters, acting via activation of the
protein kinase C
family of protein serine/threonine kinases, are able to exert profound effects on various cellular functions. In this study, we used the EL4 thymoma cell line to study the potential role of "downstream" protein serine/threonine kinases in cellular responses to phorbol esters. In wild-type EL4 cells, addition of phorbol ester caused a rapid activation of kinase activity toward RRLSSLRA (S6P). This increased activity was maintained for at least 15 min but diminished to control levels by 60 min. Activation of a myelin basic protein (MBP) kinase was also seen in response to phorbol ester. In a variant EL4 cell line in which phorbol ester does not induce
interleukin 2
transcription, phorbol ester failed to activate either the S6P kinase or MBP kinase. Partial purification of the activated S6P and MBP kinases from wild-type cells showed that they represent separate enzymes that are distinct from
protein kinase C
. Although the variant cells had reduced levels of
protein kinase C
as compared with the wild-type cells, the amount of membrane-bound enzyme increased in response to phorbol 12-myristate 13-acetate in both wild-type and variant cells. Treatment of intact cells with phorbol ester resulted in phosphorylation of some of the same protein substrates in both cell lines. Okadaic acid, a phosphatase inhibitor, increased S6P and MBP kinase activities in both wild-type and variant cells. Thus, phorbol ester failed to activate the S6P and MBP kinases in the variant cells even though these cells express activatable
protein kinase C
, S6P kinase, and MBP kinase. Two protein kinase inhibitors, staurosporine and H-7, inhibited the activity of all three kinases in vitro, while a peptide inhibitor (
PKC
19-31) showed specificity for
protein kinase C
. In summary, these results suggest that activation of messenger-independent protein kinases may be critical for certain
protein kinase C
-dependent responses.
...
PMID:Activation of messenger-independent protein kinases in wild-type and phorbol ester-resistant EL4 thymoma cells. 198 54
We have studied the effects of phorbol-dibutyrate (PBu2), a
protein kinase C
(
PKC
) activator, on the proliferation of peripheral human T cells and thymocyte subpopulations selected by treatment with monoclonal antibodies and complement: pre-thymocytes (CD1a-CD3-CD4-CD8-), cortical thymocytes (CD3-, class I- antigens) and medullary thymocytes (enriched as CD1a- cells). PBu2 induces a dose-dependent proliferative response in human peripheral blood T cells at concentrations greater than 6 ng/ml, this proliferation being mediated by the autocrine
interleukin 2
(
IL2
)/
IL2
receptor (IL2R) pathway. Pre-thymocytes respond to PBu2 in a way similar to T cells, being able to secrete
IL2
in significant amounts and express the p55 chain of IL2R. On the other hand, cortical thymocytes are not induced to proliferate after
PKC
activation and neither expression of the p55 chain of IL2R nor
IL2
secretion is observed. Human medullary thymocytes, phenotypically identical to peripheral blood T cells, show no proliferation in response to PBu2 at any concentration tested unless
IL2
is supplied to the cultures. The activation of
PKC
induces the expression of IL2R in these cells, but not
IL2
secretion. The implications of
PKC
activation in thymic maturation, the role of
IL2
and the relevance of the differences between medullary thymocytes and peripheral blood T cells are discussed.
...
PMID:Proliferative responses induced by the activation of protein kinase C during the development of human T lymphocytes. 199 83
The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) can enhance or inhibit lymphocyte proliferation. Enhancement correlated with increased
interleukin 2
(
IL-2
) production and activation of
protein kinase C
while inhibition correlated with decreased
IL-2
and downregulation of
protein kinase C
activity (D.S. Grove and A.M. Mastro, Cancer Res. 51, 82-88). In this study, various activators and inhibitors of
protein kinase C
were used in order to try to separate the effects of TPA on this enzyme from its effects on
IL-2
production and determine if
protein kinase C
activity was directly or indirectly related to
IL-2
production. 1,2-Dioctanoylglycerol, 1-oleoyl-2-acetyl-glycerol, phospholipase C, and two "rationally designed" activators, 6-(N-decylamino)-4-hydroxy-methylindole and 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol, were tested. Some activators enhanced proliferation in the presence of a Ca2+ ionophore, ionomycin, but not concanavalin A. Some activators suppressed proliferation and downregulated
protein kinase C
. Others neither downregulated
protein kinase C
nor inhibited
IL-2
production and proliferation. However, inhibition or downregulation of
protein kinase C
activity always correlated with decreased
IL-2
and depressed proliferation. Thus, the evidence in this and the previous study suggests that activation of
protein kinase C
is directly related to
IL-2
production in activated T cells.
...
PMID:Differential activation and inhibition of lymphocyte proliferation by modulators of protein kinase C: diacylglycerols, "rationally designed" activators and inhibitors of protein kinase C. 199 92
Ligand binding to the T-cell antigen receptor results in phosphatidylinositol hydrolysis and the resultant activation of
protein kinase C
, as well as the activation of a receptor-coupled protein-tyrosine kinase. As a model for tyrosine kinase activation in T cells, we used retroviral gene transfer to express the v-src oncogene in an antigen-specific murine T-cell hybridoma. Clones that expressed v-src mRNA demonstrated constitutive tyrosine phosphorylation of several cellular substrates, including the zeta chain of the T-cell receptor, and constitutive
interleukin 2
production. Thus, expression of a constitutively active protein-tyrosine kinase such as pp60v-src appears to be sufficient to induce the expression of at least one gene critical to the process of T-cell activation.
...
PMID:Expression of v-src in a murine T-cell hybridoma results in constitutive T-cell receptor phosphorylation and interleukin 2 production. 200 Mar 81
T cell activation induced via cross-linking of the T cell receptor (TcR) stimulates hydrolysis of phosphatidylinositol to the second messengers diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG is necessary for the activation and function of
protein kinase C
(
PKC
) which is suggested to play a key role in the cascade of signal transduction when translocated from the cytosol to the cell membrane. In this report, we investigated responses of resting vs. activated Ly-2+ and L3T4+ T lymphocytes in the presence of the
PKC
inhibitor H7 [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine]. H7 inhibited the induction of primary T cell proliferation, while
interleukin 2
(IL 2) production was fully retained. The effect of the
PKC
inhibitor on primary T cells depended on the type of ligand interacting with the TcR: increasing doses of concanavalin A or of immobilized anti-CD3 monoclonal antibody (mAb), but not of anti-V beta 8 or of anti-TcR alpha/beta mAb, partly overcame the blockade, indicating a differential signaling compared to the former stimuli. The blockade of T cell proliferation by H7 was not due to an inhibition of
PKC
translocation, but occurred even 4-8 h after T cell induction and correlated with a significant reduction of IL 2 receptor (IL 2R) expression. In contrast, the mRNA levels of IL 2R and the cellular proto-oncogenes c-fos and c-myc were not affected. On activated T cells, H7 neither blocked proliferation nor IL2R expression. Consequently, H7 dissects the signal resulting in T cell proliferation from those governing the triggering of other T cell functions, i.e. IL 2 production, during primary responses of Ly-2+ or L3T4+ murine T lymphocytes.
...
PMID:Dissection of signals controlling T cell function and activation: H7, an inhibitor of protein kinase C, blocks induction of primary T cell proliferation by suppressing interleukin (IL)2 receptor expression without affecting IL2 production. 206 May 74
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>